Rapid identification of novel indolylarylsulfone derivatives as potent HIV-1 NNRTIs via miniaturized CuAAC click-chemistry-based combinatorial libraries

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2024-10-15 DOI:10.1039/D4MD00469H
Ping Gao, Shu Song, Christophe Pannecouque, Erik De Clercq, Peng Zhan and Xinyong Liu
{"title":"Rapid identification of novel indolylarylsulfone derivatives as potent HIV-1 NNRTIs via miniaturized CuAAC click-chemistry-based combinatorial libraries","authors":"Ping Gao, Shu Song, Christophe Pannecouque, Erik De Clercq, Peng Zhan and Xinyong Liu","doi":"10.1039/D4MD00469H","DOIUrl":null,"url":null,"abstract":"<p >This article presents the rapid identification of novel indolylarylsulfone (IAS) derivatives as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 through a miniaturized click-chemistry-based combinatorial library approach. Utilizing copper(<small>I</small>)-catalyzed azide–alkyne cycloaddition (CuAAC), a reliable and biocompatible click chemistry technique, the researchers synthesized and characterized a series of IAS derivatives. Several compounds selected through the <em>in situ</em> enzyme inhibition assay demonstrated promising activity in subsequent cellular level tests. Notably, compound <strong>C1N4</strong> displayed the most potent anti-HIV-1 IIIB activity with an EC<small><sub>50</sub></small> of 0.024 μM and low cytotoxicity (CC<small><sub>50</sub></small> &gt; 215.88 μM). Molecular docking studies provided insights into the binding mode of these novel compounds within the NNIBP, aiding in the structure-based design of future NNRTIs. The findings underscore the potential of click chemistry in the discovery of new anti-HIV agents with improved efficacy and safety profiles.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 1","pages":" 157-167"},"PeriodicalIF":3.5970,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00469h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

This article presents the rapid identification of novel indolylarylsulfone (IAS) derivatives as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 through a miniaturized click-chemistry-based combinatorial library approach. Utilizing copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC), a reliable and biocompatible click chemistry technique, the researchers synthesized and characterized a series of IAS derivatives. Several compounds selected through the in situ enzyme inhibition assay demonstrated promising activity in subsequent cellular level tests. Notably, compound C1N4 displayed the most potent anti-HIV-1 IIIB activity with an EC50 of 0.024 μM and low cytotoxicity (CC50 > 215.88 μM). Molecular docking studies provided insights into the binding mode of these novel compounds within the NNIBP, aiding in the structure-based design of future NNRTIs. The findings underscore the potential of click chemistry in the discovery of new anti-HIV agents with improved efficacy and safety profiles.

Abstract Image

通过基于 CuAAC 点击化学的小型化组合文库,快速鉴定新型吲哚芳砜衍生物作为强效 HIV-1 NNRTIs。
本文介绍了通过一种基于微型化点击化学的组合文库方法,快速鉴定出新型吲哚芳砜(IAS)衍生物作为强效非核苷类逆转录酶抑制剂(NNRTIs)来治疗 HIV-1。研究人员利用铜(i)催化的叠氮-炔环加成(CuAAC)这一可靠且生物兼容的点击化学技术,合成了一系列IAS衍生物并对其进行了表征。通过原位酶抑制实验筛选出的几种化合物在随后的细胞水平测试中表现出了良好的活性。值得注意的是,化合物 C1N4 的 EC50 为 0.024 μM,细胞毒性较低(CC50 > 215.88 μM),具有最强的抗 HIV-1 IIIB 活性。分子对接研究深入揭示了这些新型化合物在 NNIBP 中的结合模式,有助于基于结构设计未来的 NNRTIs。这些发现强调了点击化学在发现具有更好疗效和安全性的新型抗艾滋病毒药物方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信